Pharmaceuticals 2012, 5(4), 398-404; doi:10.3390/ph5040398
Article

Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation

Rustem Zulkarneev 1 , Naufal Zagidullin 1,* email, Guzel Abdrahmanova 1 , Uta C. Hoppe 2  and Shamil Zagidullin 1
1 Bashkir State Medical University, Lenin Str. 3, Ufa 450000, Russia 2 Department of Internal Medicine II, Paracelsus Medical University, Salzburg 5020, Austria
* Author to whom correspondence should be addressed.
Received: 8 February 2012; in revised form: 25 March 2012 / Accepted: 5 April 2012 / Published: 16 April 2012
(This article belongs to the Special Issue Ivabradine)
PDF Full-text Download PDF Full-Text [353 KB, uploaded 24 April 2012 13:33 CEST]
Abstract: Accelerated sinus rhythm is an important side effect of inhaled salbutamol which is especially harmful in patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). Cross-over, randomized, open label study design. 20 patients (18 males and two females) with COPD stage II–IV and comorbide CHD NYHA class I–III were included. Spirometry with 400 mg salbutamol inhalation was performed at two consecutive days of the study. Patients in group I were prescribed 5 mg ivabradine per os 3 h before salbutamol inhalation solely on the first day of the study and patients of group II received 5 mg ivabradine only on the second day of the study. Salbutamol caused a significant increase of HR by 5.5 bpm (95% CI 0.8; 10.2, p < 0.03). After ivabradine ingestion salbutamol did not change HR significantly by −2.4 bpm (−7.0; 2.3, p = 0.33). The attenuation of HR elevation by ivabradine was significant, p < 0.01. Salbutamol alone increased FEV1 by 6.0% (2.7; 9.3, p < 0.01). This effect was not impaired by ivabradine (FEV1 increase by 7.7% (2.8; 12.6, p < 0.01 versus baseline, p = 0.5 versus no ivabradine). Ivabradine 5 mg per os prevents heart rate acceleration after inhalation of 400 mg salbutamol. Ivabradine has no impact on lung function in patients with moderate-to-very-severe COPD and CHD comorbidity.
Keywords: ivabradine; COPD; CHD; salbutamol

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Zulkarneev, R.; Zagidullin, N.; Abdrahmanova, G.; Hoppe, U.C.; Zagidullin, S. Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation. Pharmaceuticals 2012, 5, 398-404.

AMA Style

Zulkarneev R, Zagidullin N, Abdrahmanova G, Hoppe UC, Zagidullin S. Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation. Pharmaceuticals. 2012; 5(4):398-404.

Chicago/Turabian Style

Zulkarneev, Rustem; Zagidullin, Naufal; Abdrahmanova, Guzel; Hoppe, Uta C.; Zagidullin, Shamil. 2012. "Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation." Pharmaceuticals 5, no. 4: 398-404.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert